お知らせ • Jul 12
Evelo Biosciences, Inc. Announces Management Changes
Evelo Biosciences, Inc. announced On July 7, 2023, each of Julie H. McHugh, John A. Hohneker, M.D., Iain B. McInnes, M.B.Ch.B., Ph.D., and Theodose Melas-Kyriazi notified the Company of such person’s resignation from the Board of Directors (the “Board”) of the Company and all associated committees, subject to and effective upon the consummation of the Private Placement. In each case, the resignation of each director was not the result of a disagreement with the Company. In connection with the foregoing resignations, the Board reduced its size from nine to seven directors subject to and effective upon the consummation of the Private Placement. On July 7, 2023, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Jeffrey R. Moore to the Board as a Class I director to serve until the Company’s annual meeting of stockholders to be held in 2025 and until his successor is duly elected and qualified or his earlier death, disqualification, resignation or removal, subject to and effective upon the consummation of the Private Placement. Mr. Moore was also appointed as the Chair of the Audit Committee of the Board. Mr. Moore has served as Senior Vice President, Facilities & Venture Debt at Flagship Pioneering (“Flagship”), a company that conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability since November 2021 and focuses on leading real estate and venture debt for the company. Prior to this, from June 2019 to November 2021, Mr. Moore served as Chief Financial Officer at Flagship Pioneering Labs, providing financial oversight to approximately 25 Flagship entities. Prior to joining Flagship, Mr. Moore served as Senior Vice President of Finance and Administration at Kaleido Biosciences, Inc., a pharmaceutical company, from June 2017 to June 2019, where he oversaw the company’s finance and accounting department as it transitioned to a public company. Mr. Moore has served in similar finance and administrative roles with a number of pharmaceutical companies, including Helicos BioSciences, Inc., Axcella Health, Inc. and PerSeptive Biosystems, Inc. Mr. Moore received a B.S. in agricultural economics from Cornell University and an M.B.A. from Vanderbilt University. Also on July 7, 2023, upon the recommendation of the Nominating Committee, the Board appointed Alexander C. Reynolds to the Board as a Class III director to serve until the Company’s annual meeting of stockholders to be held in 2024 and until his successor is duly elected and qualified or his earlier death, disqualification, resignation or removal, subject to and effective upon the consummation of the Private Placement. Mr. Reynolds was also appointed as the Chair of the Nominating Committee and a member of the Audit Committee. Mr. Reynolds serves as Chief Operating Officer, Pioneering Medicines at Flagship. He joined Flagship in May 2020 and is responsible for building the operations model and portfolio strategy for his department. Prior to his role at Flagship, from July 2007 to January 2020, Mr. Reynolds held various roles at Celgene Corporation, a pharmaceutical company, including as Corporate Vice President of the Global Project Leadership team responsible for late-stage development projects in oncology and immunology. Prior to his roles at Celgene, Mr. Reynolds also worked at the U.S. Treasury, The Carlyle Group and Morgan Stanley. Mr. Reynolds received an A.B. in politics from Princeton University and an M.B.A. from the University of Virginia Darden Graduate School of Business. Each of Messrs. Moore and Reynolds is eligible to participate in the Company’s Non-Employee Director Compensation Program, which provides for, among other things: an annual cash retainer of $40,000 and, upon joining the Board, an option to purchase 2,000 shares (on a post-reverse stock split basis) of the Company’s Common Stock (the “Initial Equity Award”). Mr. Moore is eligible to receive an annual cash retainer of $15,000 for service as Chair of the Audit Committee, and Mr. Reynolds is eligible to receive an annual cash retainer of $7,500 for service as a member of the Audit Committee and an annual cash retainer of $8,000 for service as Chair of the Nominating Committee. The Initial Equity Award has an exercise price equal to the fair market value of a share of the Company’s Common Stock on the grant date, and will vest and become exercisable in thirty-six substantially equal monthly installments following the grant date, subject, to Mr. Moore’s and Mr. Reynold’s respective continued service on the Board through each applicable vesting date.